Efficacy News and Research

RSS
FDA approves Organogenesis oral soft tissue regeneration product, GINTUIT

FDA approves Organogenesis oral soft tissue regeneration product, GINTUIT

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

FDA may allow many chronic ailment drugs to be available over-the-counter

FDA may allow many chronic ailment drugs to be available over-the-counter

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

BfArM grants Moberg Derma approval to initiate Limtop clinical phase I trial for actinic keratosis

Emergent BioSolutions fourth quarter total revenues increase to $107.9M

Emergent BioSolutions fourth quarter total revenues increase to $107.9M

IDRI receives $1 million RHSC grant to eliminate leprosy

IDRI receives $1 million RHSC grant to eliminate leprosy

Genetically modified pig may hold keys to develop treatments for RP

Genetically modified pig may hold keys to develop treatments for RP

Enrollment complete in Palatin's bremelanotide Phase 2B trial for FSD

Enrollment complete in Palatin's bremelanotide Phase 2B trial for FSD

MEDVAMC initiates Aeterna Zentaris' AEZS-130 Phase 2A trial in cancer cachexia

MEDVAMC initiates Aeterna Zentaris' AEZS-130 Phase 2A trial in cancer cachexia

Positive phase II trial results from Circassia's ragweed allergy therapy

Positive phase II trial results from Circassia's ragweed allergy therapy

MRF clinical trial to examine antigen-specific MS therapy

MRF clinical trial to examine antigen-specific MS therapy

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Zalicus fourth quarter revenue decreases to $8.2 million

Zalicus fourth quarter revenue decreases to $8.2 million

BioLineRx receives European patent for BL-1020 to treat schizophrenia

BioLineRx receives European patent for BL-1020 to treat schizophrenia

Celldex fourth quarter net loss increases to $12.7 million

Celldex fourth quarter net loss increases to $12.7 million

Research team identifies preventive care guidelines relevant to young adults

Research team identifies preventive care guidelines relevant to young adults

AMTR soon after failure of AEDs may reduce risk of seizures in epilepsy patients

AMTR soon after failure of AEDs may reduce risk of seizures in epilepsy patients

Physicians study human stem cell use as possible treatment for ischemic stroke

Physicians study human stem cell use as possible treatment for ischemic stroke

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.